Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 3
2016 3
2017 1
2018 1
2019 1
2020 4
2023 3
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma.
Kostyrko K, Román M, Lee AG, Simpson DR, Dinh PT, Leung SG, Marini KD, Kelly MR, Broyde J, Califano A, Jackson PK, Sweet-Cordero EA. Kostyrko K, et al. Nat Commun. 2023 Jul 5;14(1):3966. doi: 10.1038/s41467-023-39591-2. Nat Commun. 2023. PMID: 37407562 Free PMC article.
CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities.
Han K, Pierce SE, Li A, Spees K, Anderson GR, Seoane JA, Lo YH, Dubreuil M, Olivas M, Kamber RA, Wainberg M, Kostyrko K, Kelly MR, Yousefi M, Simpkins SW, Yao D, Lee K, Kuo CJ, Jackson PK, Sweet-Cordero A, Kundaje A, Gentles AJ, Curtis C, Winslow MM, Bassik MC. Han K, et al. Among authors: kostyrko k. Nature. 2020 Apr;580(7801):136-141. doi: 10.1038/s41586-020-2099-x. Epub 2020 Mar 11. Nature. 2020. PMID: 32238925 Free PMC article.
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.
Thatikonda V, Lyu H, Jurado S, Kostyrko K, Bristow CA, Albrecht C, Alpar D, Arnhof H, Bergner O, Bosch K, Feng N, Gao S, Gerlach D, Gmachl M, Hinkel M, Lieb S, Jeschko A, Machado AA, Madensky T, Marszalek ED, Mahendra M, Melo-Zainzinger G, Molkentine JM, Jaeger PA, Peng DH, Schenk RL, Sorokin A, Strauss S, Trapani F, Kopetz S, Vellano CP, Petronczki M, Kraut N, Heffernan TP, Marszalek JR, Pearson M, Waizenegger IC, Hofmann MH. Thatikonda V, et al. Among authors: kostyrko k. Nat Cancer. 2024 Sep;5(9):1352-1370. doi: 10.1038/s43018-024-00800-6. Epub 2024 Aug 5. Nat Cancer. 2024. PMID: 39103541 Free PMC article.
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.
Norgard RJ, Budhani P, O'Brien SA, Xia Y, Egan JN, Flynn B, Tagore JR, Seco J, Peet GW, Mikucka A, Wasti R, Chan LC, Hinkel M, Martinez-Morilla S, Pignatelli J, Trapani F, Corse E, Feng D, Kostyrko K, Hofmann MH, Liu K, Kashyap AS. Norgard RJ, et al. Among authors: kostyrko k. Cancer Res Commun. 2024 Jun 21;4(6):1548-1560. doi: 10.1158/2767-9764.CRC-24-0172. Cancer Res Commun. 2024. PMID: 38727236 Free PMC article.
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
Kim JW, Marquez CP, Kostyrko K, Koehne AL, Marini K, Simpson DR, Lee AG, Leung SG, Sayles LC, Shrager J, Ferrer I, Paz-Ares L, Gephart MH, Vicent S, Cochran JR, Sweet-Cordero EA. Kim JW, et al. Among authors: kostyrko k. Nat Med. 2019 Nov;25(11):1783-1795. doi: 10.1038/s41591-019-0612-2. Epub 2019 Nov 7. Nat Med. 2019. PMID: 31700175 Free PMC article.
SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma.
Daley BR, Sealover NE, Sheffels E, Hughes JM, Gerlach D, Hofmann MH, Kostyrko K, Mair B, Linke A, Beckley Z, Frank A, Dalgard C, Kortum RL. Daley BR, et al. Among authors: kostyrko k. bioRxiv [Preprint]. 2023 Dec 15:2023.12.07.570642. doi: 10.1101/2023.12.07.570642. bioRxiv. 2023. Update in: Cancer Res. 2025 Jan 2;85(1):118-133. doi: 10.1158/0008-5472.CAN-23-3256. PMID: 38106234 Free PMC article. Updated. Preprint.
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.
Valencia K, Erice O, Kostyrko K, Hausmann S, Guruceaga E, Tathireddy A, Flores NM, Sayles LC, Lee AG, Fragoso R, Sun TQ, Vallejo A, Roman M, Entrialgo-Cadierno R, Migueliz I, Razquin N, Fortes P, Lecanda F, Lu J, Ponz-Sarvise M, Chen CZ, Mazur PK, Sweet-Cordero EA, Vicent S. Valencia K, et al. Among authors: kostyrko k. J Clin Invest. 2020 Apr 1;130(4):1879-1895. doi: 10.1172/JCI129012. J Clin Invest. 2020. PMID: 31874105 Free PMC article.
18 results